DK2441466T3 - MIC-1-inhiberende middel - Google Patents

MIC-1-inhiberende middel

Info

Publication number
DK2441466T3
DK2441466T3 DK11183884.3T DK11183884T DK2441466T3 DK 2441466 T3 DK2441466 T3 DK 2441466T3 DK 11183884 T DK11183884 T DK 11183884T DK 2441466 T3 DK2441466 T3 DK 2441466T3
Authority
DK
Denmark
Prior art keywords
mic
inhibitor
Prior art date
Application number
DK11183884.3T
Other languages
English (en)
Inventor
Samuel Norbet Briet
Asne Rhoda Bauskin
Original Assignee
St Vincents Hosp Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2441466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hosp Sydney filed Critical St Vincents Hosp Sydney
Application granted granted Critical
Publication of DK2441466T3 publication Critical patent/DK2441466T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK11183884.3T 2004-04-13 2005-04-13 MIC-1-inhiberende middel DK2441466T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP05729508.1A EP1734986B1 (en) 2004-04-13 2005-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
DK2441466T3 true DK2441466T3 (da) 2014-10-27

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten

Country Status (12)

Country Link
US (6) US8192735B2 (da)
EP (4) EP2441466B1 (da)
JP (4) JP5448338B2 (da)
CA (2) CA2905125C (da)
CY (1) CY1115731T1 (da)
DK (2) DK2929891T3 (da)
ES (3) ES2518865T3 (da)
HK (2) HK1215932A1 (da)
PL (2) PL2441466T3 (da)
PT (2) PT2441466E (da)
SI (1) SI2441466T1 (da)
WO (1) WO2005099746A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192735B2 (en) * 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
CN106018820B (zh) * 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
CN101896192A (zh) * 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
ES2434996T3 (es) * 2008-10-31 2013-12-18 St Vincent's Hospital Sydney Limited Métodos de pronóstico en enfermedad renal crónica
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2886207C (en) 2012-09-26 2021-01-05 Jorg Wischhusen Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
EA038645B1 (ru) 2012-12-21 2021-09-28 Авео Фармасьютикалз, Инк. Антитела к gdf15
AU2014212640B2 (en) 2013-01-30 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR102376451B1 (ko) 2013-07-31 2022-03-23 암젠 인크 성장 분화 인자 15(ｇｄｆ-15) 작제물
PT3653644T (pt) * 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
JP6768527B2 (ja) * 2014-06-20 2020-10-14 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
US20170107248A1 (en) * 2014-06-23 2017-04-20 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
EP3174894B1 (en) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PT3197493T (pt) * 2014-09-25 2021-06-04 Aveo Pharmaceuticals Inc Métodos para reverter a caquexia e prolongar a sobrevivência que compreendem a administração de um modulador de gdf15 e um agente anti-carcinogénico
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3237440A1 (en) * 2014-12-22 2017-11-01 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof
ES2968226T3 (es) 2015-10-02 2024-05-08 Univ Wuerzburg J Maximilians GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
EP3355919B1 (en) 2015-10-02 2022-12-07 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
CN108700573B (zh) 2016-02-29 2021-06-11 公立大学法人横滨市立大学 检测去势抵抗性前列腺癌的方法和检测试剂
US10174119B2 (en) 2016-03-31 2019-01-08 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
AU2017342028A1 (en) * 2016-10-12 2019-04-11 Janssen Biotech, Inc. Methods for screening for modulators of GDF15-like biological activity
EP3551214B1 (en) 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
US11260108B2 (en) 2017-09-10 2022-03-01 Novo Nordisk A/S MIC-1 and GLP-1 for use in the treatment of obesity
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
CN112912395A (zh) 2018-08-20 2021-06-04 辉瑞公司 抗gdf15抗体、组合物和使用方法
US11810670B2 (en) 2018-11-13 2023-11-07 CurieAI, Inc. Intelligent health monitoring
US20230002460A1 (en) 2019-11-26 2023-01-05 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
EP4351628A1 (en) 2021-05-21 2024-04-17 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
CA3219645A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ310370A (en) 1995-06-22 2001-04-27 St A TGF-beta like cytokine designated pCL13
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
EP1117805A2 (en) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modified tgf-beta superfamily proteins
AU2001250182B2 (en) * 2000-04-20 2006-06-08 St Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US8192735B2 (en) 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
SI1844337T1 (sl) * 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
US20100204123A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease

Also Published As

Publication number Publication date
JP2011190262A (ja) 2011-09-29
CA2561877A1 (en) 2005-10-27
PT2929891T (pt) 2020-04-08
US8946146B2 (en) 2015-02-03
JP2014051511A (ja) 2014-03-20
EP2774620A1 (en) 2014-09-10
EP1734986A1 (en) 2006-12-27
JP5448338B2 (ja) 2014-03-19
SI2441466T1 (sl) 2015-01-30
PL2929891T3 (pl) 2020-08-24
EP2441466B1 (en) 2014-07-23
CY1115731T1 (el) 2017-01-25
US20090004181A1 (en) 2009-01-01
PT2441466E (pt) 2014-09-09
EP1734986A4 (en) 2009-07-22
US20150183861A1 (en) 2015-07-02
WO2005099746A1 (en) 2005-10-27
JP2013209376A (ja) 2013-10-10
CA2905125A1 (en) 2005-10-27
ES2555956T3 (es) 2016-01-11
CA2905125C (en) 2017-02-07
US8192735B2 (en) 2012-06-05
EP2929891B1 (en) 2020-03-11
HK1168274A1 (en) 2012-12-28
HK1215932A1 (zh) 2016-09-30
US20110123454A1 (en) 2011-05-26
US20180346560A1 (en) 2018-12-06
ES2788868T3 (es) 2020-10-23
EP2929891A1 (en) 2015-10-14
US20210340243A1 (en) 2021-11-04
DK2929891T3 (da) 2020-05-11
PL2441466T3 (pl) 2015-01-30
EP1734986B1 (en) 2015-11-11
JP5767667B2 (ja) 2015-08-19
US20160289320A1 (en) 2016-10-06
JP2007532586A (ja) 2007-11-15
CA2561877C (en) 2017-03-14
ES2518865T3 (es) 2014-11-05
EP2441466A1 (en) 2012-04-18
JP5806275B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
DK2441466T3 (da) MIC-1-inhiberende middel
CY2019034I1 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DE112005001624A5 (de) Brillengestell
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE459633T1 (de) Makrolide
DE502005004842D1 (de) Wischblatt
IS8531A (is) Steypumótunarvél
NO20044110L (no) Stromskinne
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005004695D1 (de) Sicherheitsfangseil
DE502004012213D1 (de) Flachdichtung
AT500198B1 (de) Ladewagen
DE202004017327U1 (de) Fitnessrad
ATE389633T1 (de) Omega-phenyloctanamide
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005004160D1 (de) Seitenblinkleuchte
AT500249A3 (de) Scheibenegge
DE502005003159D1 (de) Kettenstichnähvorrichtung
FR2865904B1 (fr) Calecon remonte fesses
DE502004001961D1 (de) Barikadenbrecher
DE112005002245A5 (de) Polymerdichtung
DE112005001019A5 (de) Kunststoffschraubverschlusskappe
ATA482004A (de) Tuba-dämpfer
AT7802U3 (de) Parfum-zerstäuber